A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Healthy
Interventions
DRUG

JNJ-28431754/ Placebo

Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.

DRUG

JNJ-28431754

Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT01177150 - A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter